Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.41 |
| ▸ | SETD2 | Q9BYW2 | 2/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 2/20 | 0.40 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.40 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.39 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.39 |
| ▸ | GAPDH | P04406 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300400 | 1.00 | ADORA2A (0.41) | ADORA2ASETD2SMYD3PI4KAPI4K2B | |
| SCHEMBL18011012 | 0.90 | SETD2 (0.44) | ADORA2ASETD2SMYD3PI4KAPI4K2B | |
| SCHEMBL18011010 | 0.90 | SETD2 (0.44) | ADORA2ASETD2SMYD3PI4KAPI4K2B | |
| SCHEMBL1275036 | 0.85 | TARS1 (0.46) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30862415 | 0.85 | TARS1 (0.46) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL2185027 | 0.85 | TARS1 (0.46) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL28824008 | 0.83 | ADORA2A (0.43) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL7226462 | 0.82 | ADORA3 (0.51) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL15798672 | 0.82 | ADORA3 (0.45) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6536153 | 0.80 | PI4KA (0.46) | ADORA2API4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014039809-A2 | CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2014-03-13 | — | — | WO | claimed |
| US-12584149-B2 | Nuclease-mediated genome editing of primary cells and related kits | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260069541-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-12533318-B2 | Jet mixing lipid nanoparticle manufacturing process | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-01-27 | — | — | US | disclosed |
| US-12527742-B2 | Methods for manufacturing a liposome encapsulated RNA | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2026-01-20 | — | — | US | disclosed |
| US-20260014185-A1 | Delivery of RNA to Different Cell Types | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-01-15 | — | — | US | disclosed |
| EP-4665380-A1 | INTERLEUKIN FORMULATIONS FOR IN VIVO USE | Akron BioProducts LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250302860-A1 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-10-02 | — | — | US | disclosed |
| US-20250302925-A1 | CONJUGATED CRISPR-CAS COMPLEXES | SYNTHEGO CORPORATION | 2025-10-02 | — | — | US | disclosed |
| US-20250275999-A1 | HIGH PURITY RNA COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | MODERNATX, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| WO-2012031046-A2 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN-CODING RNA | NOVARTIS AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031043-A1 | PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA | NOVARTIS AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012006378-A1 | LIPOSOMES WITH LIPIDS HAVING AN ADVANTAGEOUS PKA- VALUE FOR RNA DELIVERY | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006376-A2 | VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA MOLECULES | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006359-A1 | DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006372-A1 | DELIVERY OF RNA TO DIFFERENT CELL TYPES | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006369-A2 | IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006377-A2 | DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011071931-A2 | RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLS | KARIKO KATALIN (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20110143397-A1 | RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584149-B2 | Nuclease-mediated genome editing of primary cells and related kits | ADAR, RNASE1, CPSF6 | ADORA2A 728/4885SETD2 3739/4885SMYD3 2215/4885 |
| US-12533318-B2 | Jet mixing lipid nanoparticle manufacturing process | AUP1, LNPK, LIPA | ADORA2A 3511/4885SETD2 2466/4885SMYD3 811/4885 |
| US-12527742-B2 | Methods for manufacturing a liposome encapsulated RNA | MTREX, AGO2, EXOSC9 | ADORA2A 2730/4885SETD2 1084/4885SMYD3 466/4885 |
| US-20260069541-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | PHAX, RNMT, PRKCZ | ADORA2A 2107/4885SETD2 2944/4885SMYD3 1322/4885 |
| US-20250302925-A1 | CONJUGATED CRISPR-CAS COMPLEXES | DCLRE1B, MRE11, FEN1 | ADORA2A 3894/4885SETD2 3745/4885SMYD3 3586/4885 |
| US-20260014185-A1 | Delivery of RNA to Different Cell Types | NUP205, NSUN3, NPC1 | ADORA2A 4264/4885SETD2 235/4885SMYD3 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.